Chemomab Therapeutics: Advancing CM-101 with Strategic Financial Optimizations and FDA Support

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on CMMB stock, giving a Buy rating today.

Michael Okunewitch’s rating is based on several compelling factors. Chemomab Therapeutics is advancing its innovative therapeutic, CM-101, which targets the CCL24 protein involved in fibrosis and inflammation, into a streamlined Phase 3 clinical trial. The company has received positive feedback from the FDA, which supports their approach and allows for a more efficient trial process. This regulatory endorsement, combined with the promising Phase 2 data that has been well-received in scientific circles, underscores the potential of CM-101 in addressing unmet medical needs.
Additionally, Chemomab’s strategic adjustments, such as the reverse split of its ADS ratio, aim to optimize its financial structure and market presence. The company’s financial position, with a cash runway extending into the second quarter of 2026, provides a stable foundation to pursue these clinical advancements. The valuation model anticipates commercialization of CM-101 in primary sclerosing cholangitis by 2029 and systemic sclerosis by 2031, with a calculated price target of $7.00, reflecting the potential for significant future growth.

In another report released today, Oppenheimer also maintained a Buy rating on the stock with a $10.00 price target.